Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment

The study will evaluate the effectiveness, safety and tolerability of tacrolimus lipid suspension for enema in adult patients with mild to moderately active ulcerative colitis who had an inadequate response or intolerance of at least 1 of aminosalicylates (5-ASAs), corticosteroids, azothiopurine, mercaptopurine and methotrexate and need an alternative therapy. There will be approximately 150 male and female subjects of 18 and 65 years of age enrolled. Patients will be randomized into two groups where Tacrolimus Lipid Suspension for Enema or Placebo (Tacrolimus-free) Lipid Suspension for Enema will be administered rectally once daily for 28 days.

NCT Number	NCT06867042
Lead Sponsor	Jina Pharmaceuticals Inc. Collaborators: Novum Pharmaceutical Research Services
Conditions	Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Enrollment	150 participants
Start Date	2025-04
Primary Completion	2025-12 (estimated)
Study Completion	2026-04 (estimated)
Updated on ClinicalTrials.gov	2025-03-12